



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## Regorafenib-<sup>13</sup>C-d<sub>3</sub>

Item No. 25486

CAS Registry No.: 2126178-55-8

Formal Name: 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-<sup>13</sup>C-d<sub>3</sub>)-2-pyridinecarboxamide

MF: C<sub>20</sub>[<sup>13</sup>C]H<sub>12</sub>D<sub>3</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>3</sub>

FW: 486.8

Chemical Purity: ≥98% (Regorafenib)


Deuterium

Incorporation: ≥99% deuterated forms (d<sub>1</sub>-d<sub>3</sub>); ≤1% d<sub>0</sub>

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Regorafenib-<sup>13</sup>C-d<sub>3</sub> is intended for use as an internal standard for the quantification of regorafenib (Item No. 18498) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Regorafenib-<sup>13</sup>C-d<sub>3</sub> is supplied as a solid. A stock solution may be made by dissolving the regorafenib-<sup>13</sup>C-d<sub>3</sub> in the solvent of choice. Regorafenib-<sup>13</sup>C-d<sub>3</sub> is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of regorafenib-<sup>13</sup>C-d<sub>3</sub> in ethanol is approximately 14 mg/ml and approximately 30 mg/ml in DMSO and DMF.

### Description

Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.<sup>1</sup> It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC<sub>50</sub> values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC<sub>50</sub>s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.<sup>1-3</sup> *In vivo*, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.<sup>1</sup> It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

### References

1. Wilhelm, S.M., Dumas, J., Adnane, L., *et al.* Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. *Int. J. Cancer* **129**(1), 245-255 (2011).
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., *et al.* Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. *PLoS One* **9**(3), 1-13 (2014).
3. Ravi, S. and Singal, A.K. Regorafenib: An evidence-based review of its potential in patients with advanced liver cancer. *Core Evid.* **9**, 81-87 (2014).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2018

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM